CRSP icon

CRISPR Therapeutics
CRSP

Overview Fund Activity

444 hedge funds and large institutions have $3.47B invested in CRISPR Therapeutics in 2022 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 170 increasing their positions, 97 reducing their positions, and 65 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
444
Holders Change
–
Holders Change %
0%
% of All Funds
7.03%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
72
Increased
170
Reduced
97
Closed
65
Calls
$149M
Puts
$156M
Net Calls
-$6.94M
Net Calls Change
-$24M

Top Buyers

1
Sumitomo Mitsui Trust Group
1
Sumitomo Mitsui Trust Group
Japan
$290M
2
BlackRock
2
BlackRock
New York
$143M
3
Fidelity Investments
3
Fidelity Investments
Massachusetts
$79.2M
4
Vanguard Group
4
Vanguard Group
Pennsylvania
$76.4M
5
Geode Capital Management
5
Geode Capital Management
Massachusetts
$41.6M

Top Sellers

1
EC
1
EcoR1 Capital
California
$0
2
Capital World Investors
2
Capital World Investors
California
$0
3
Jennison Associates
3
Jennison Associates
New York
$0
4
American Century Companies
4
American Century Companies
Missouri
$0
5
Millennium Management
5
Millennium Management
New York
$2.87M
Name Holding Trade Value Shares
Change 		Shares
Change %
MTWM
501
Masso Torrence Wealth Management
New Jersey
– -$1K -13 Closed
SPA
502
Shore Point Advisors
New Jersey
– -$1K -7 Closed
17 18 19 20
21